Verve Not Ready To Pull Plug On Anti-PCSK9 Gene Editing Candidate
But Firm Shifts Focus To Back-Up Candidate
Executive Summary
The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.